Strong financial performance and positive developments in the R&D pipeline 

Published on 28 October 2026

“

We delivered a strong third quarter. We achieved important milestones in our long-term growth strategy, with expansion of our clinical pipeline and continued strengthening of our licensing portfolio.

"We delivered a strong third quarter, with revenue growth driven by the Innovative Medicines and Branded Products business divisions. Profitability improved mostly due to an increase in royalty income. We achieved important milestones in our long-term growth strategy, with expansion of our clinical pipeline and continued strengthening of our licensing portfolio. 

Nubeqa® maintained its strong growth trajectory and was the main driver of the increase in net sales. Performance was also supported by the Easyhaler® product portfolio and the Women’s Health portfolio, where sales benefited from strong demand. In the CNS therapy area, the growth mainly came from other products than entacapone. 

During the quarter, we advanced our pipeline by initiating a Phase 1 clinical trial with our first large molecule asset. Advancing the bispecific antibody ODM-216 into clinical development is a significant milestone for Orion and demonstrates the breadth of our R&D capabilities. Our sustained investment in early-stage research is translating into one of the broadest clinical pipelines in Orion's history. We are excited about this progress and expect to advance further assets into clinical development in the coming months. After the review period, interim results from the DASL-HiCaP Phase 3 trial were announced at the ESMO 2026 congress. These interim results indicate that darolutamide could be a potential treatment option in earlier prostate cancer disease setting.

We have signed two important Europe-wide licensing agreements during the year, most recently in early October. The biosimilars covered by these agreements are still under development, but they have the potential to support the future growth of our business in the 2030s.

After the review period, we announced adjustments to the composition and responsibilities of the Orion Executive Team. The renewed structure brings our organisation more closely in line with our strategic priorities. We will be better focused on innovative medicines and branded products, stronger in commercial execution in our current markets, and building the capabilities needed to drive future growth. 

Due to the strong growth of Nubeqa® royalties, we have upgraded our financial outlook for 2026. I would like to thank all our employees for their excellent work and contribution during the quarter. We have positive momentum going into the final quarter of the year, and I look forward to continuing this work together.”